Toronto advised MedReleaf Corp. in its $100.5 million “bought deal” prospectus offering

December 4, 2017

Client: MedReleaf Corp.

Our Toronto office advised MedReleaf Corp. (“MedReleaf” or the “Company”) in connection with its $100,501,530 short form prospectus offering and secondary offering, on a “bought deal” basis of 6,072,600 common shares of the Company at a price of $16.55 per share (the “Offering”), whereby the Company issued and sold a total of 3,625,470 shares (the “Treasury Offering”) and certain selling shareholders offered and sold an aggregate of 2,447,130 shares.

The Offering was underwritten by a syndicate of underwriters led by GMP Securities L.P., as lead underwriter and sole bookrunner, Canaccord Genuity Corp., Clarus Securities Inc., Cormark Securities Inc. and PI Financial Corp.

The Company intends to use the net proceeds from the Offering to finance the acquisition and/or construction of additional cannabis production and manufacturing facilities in Canada as well as in other jurisdictions with federal legal cannabis markets, where warranted by the opportunities available to MedReleaf, and the expansion of the Company’s marketing and sales initiatives.

The Toronto team was led by Paul Fitzgerald and Sean Williamson.